← Leaderboards
Patrick A Brown
Johns Hopkins University
$1,041,781
Attributed
$1,382,911
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $360.3K · FY2006–12$500K$375K$250K$125K$0
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$1,382,911 · 2
By mechanism
K23$700,650 · 1
R21$682,261 · 1
Top collaborators
- Michael James Burke3 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Donald Small$15,602,119
- Richard J Jones$17,555,212
- Mark J Levis$4,468,842
- Michael J Borowitz$4,928,476
- Richard F. Ambinder$9,273,650
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseClinical TrialsLeukemia, Lymphocytic, AcuteSamplingChildhood LeukemiaChildhoodIn VitroLeukemiaMalignant NeoplasmsResponseResistance MechanismPharmaceutical PreparationsApoptosisCessation Of LifeChemotherapyChildCell Cycle ProgressionAdult Acute Myeloblastic LeukemiaCareerEnvironmentFailure (Biologic Function)Flt3 GeneCytotoxicBlast Cell
Grant awards (8)
A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL$261,845
R21 · FY2012 · CA
A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL$60,086
R21 · FY2012 · CA
A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL$360,330
R21 · FY2011 · CA
Developing FLT3-Targeted Therapy for Pediatric Leukemia$140,130
K23 · FY2010 · CA · contact PI
Developing FLT3-Targeted Therapy for Pediatric Leukemia$140,130
K23 · FY2009 · CA · contact PI
Developing FLT3-Targeted Therapy for Pediatric Leukemia$140,130
K23 · FY2008 · CA · contact PI
Developing FLT3-Targeted Therapy for Pediatric Leukemia$140,130
K23 · FY2007 · CA · contact PI
Developing FLT3-Targeted Therapy for Pediatric Leukemia$140,130
K23 · FY2006 · CA · contact PI